Novel topical and oral treatment for dermatitis and psoriasis

Drug Discovery Today

Volumn 6, Issue 3, 2001, Pages 114-115

  Lawrence, Rebecca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; PIMECROLIMUS;

ATOPIC DERMATITIS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; PATHOPHYSIOLOGY; PSORIASIS; SHORT SURVEY; SIDE EFFECT; SKIN INFLAMMATION; T LYMPHOCYTE;

EID: 0035253272     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01623-8     Document Type: Short Survey

References (14)

1. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases?
2. Antiinflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis
3. Immunophilins as drug targets
4. Clearing of psoriasis by a novel immunosuppressive macrolide
5. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology
6. A potential new anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology
7. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981
8. SDZ ASM 981: Mode of action and pharmacological selectivity
9. SDZ ASM 981 1% cream demonstrates efficacy and safety in paediatric atopic dermatitis patients
10. SDZ ASM 981: pharmacokinetics in adults and children
11. SDZ ASM 981 is safe and effective for long-term use in atopic dermatitis
12. SDZ ASM 981 does not induce skin atrophy: a randomized, double-blind controlled study
13. Oral SDZ ASM 981: safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis